[Review of current pharmacologic treatment of pain].

Abstract:

:Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are now widely acknowledged. There can be no doubt about the physical component of pain, but the psychological and social aspects should not be ignored, particularly in the case of chronic pain. There is no single therapeutic approach to pain and, more often than not, successful treatment comprises a combination of several. Pharmacological treatments are undeniably the most common approach. In clinical practice, recent advances have been based upon an improved understanding of 'old' substances such as morphine and, at the same time, research continues in the hope of finding the 'ideal' analgesic-effective in most situations but without adverse effects: this appears to be a somewhat utopian arm at present, considering the number of different causes of pain. An improved understanding of the physiological mechanisms of pain has led, within the field of clinical practice, to several methods of differentiating pain. These depend on whether or not pain responds to morphine, or on the type of pain: pain due to an excess of nociception, pain resulting from deafferentation (caused by damage to nerve pathways) in the central or peripheral nervous system and psychogenic (idiopathic) pain. Likewise, there are several different ways of classifying analgesic treatments: according to the intensity of pain, as with use of the WHO ladder (which is based on the notion of steps) for the treatment of cancer pain; according to the presumed physiopathological mechanism and, in particular, the response to morphine, and according to the presumed central or peripheral mechanism of the drugs. In reality, peripherally acting drugs can also have a central mechanism of action, just as drugs known to have a central mechanism of action can also have peripheral activity. As a result, several therapeutic classes have been identified. Firstly NSAIDs, which act by inhibiting the enzymes that synthesise prostaglandins, cyclooxygenases (COX-1, COX-2), but which also act upon lipo-oxygenases: Their efficacy is interesting, although somewhat limited by both their ceiling effect and the frequent adverse gastrointestinal reactions they produce. Specific inhibitors of COX-2 could well reduce the risk of adverse effects. Opioids constitute the first-line treatment for pain, particularly severe pain. There are several classifications for these drugs. Firstly, weak opioids (such as codeine) and strong opioids (such as morphine) are differentiated. Secondly, a distinction is made between pure agonists (such as morphine), partial agonists (such as buprenorphine), agonist-antagonists (such as nalbuphine) and antagonists (such as naloxone). Finally, agents are distinguished on the basis of their chemical structure (synthetic, semi-synthetic or natural derivatives). These molecules act upon different receptors (mu, delta, kappa, sigma) and, although peripheral mechanisms have been described, their activity occurs mainly at spinal and supraspinal levels. They provide a potent analgesic effect but are also responsible for various adverse effects-nausea, vomiting, sedation, constipation and respiratory depression-which seriously limit their use. As long as the indication is appropriate, these drugs should not be withheld because of fear of dependence or abuse. It has been observed that other adjuvant therapeutic approaches, generally used to treat conditions other than pain, provide pain relief in certain situations. These include corticosteroids, which are-widely used in rheumatology and oncology, and antidepressants, which are frequently used to treat chronic pain, especially that with a neuropathic component. Anti-epileptics are also used, particularly for excrutiating

journal_name

Drugs

journal_title

Drugs

authors

Brasseur L

doi

10.2165/00003495-199700532-00005

subject

Has Abstract

pub_date

1997-01-01 00:00:00

pages

10-7

eissn

0012-6667

issn

1179-1950

journal_volume

53 Suppl 2

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0634-8

    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00

  • Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy.

    abstract::Significant progress has been made in the battle against transmission of HIV-1 from mother to infant. Antiretroviral regimens covering the later part of gestation, labour and the first few weeks of neonatal life have shown great efficacy in reducing such transmission. With the advent of combination antiretroviral ther...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262150-00004

    authors: Kourtis AP

    更新日期:2002-01-01 00:00:00

  • Anagrelide: a review of its use in the management of essential thrombocythaemia.

    abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666010-00006

    authors: Wagstaff AJ,Keating GM

    更新日期:2006-01-01 00:00:00

  • Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

    abstract:BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0382-1

    authors: Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

    更新日期:2015-04-01 00:00:00

  • Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

    abstract::Azacitidine (Vidaza) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to Intern...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202840-000000000-00000

    authors: Keating GM

    更新日期:2009-01-01 00:00:00

  • Pruritus. Current concepts in pathogenesis and treatment.

    abstract::Pruritus is an unpleasant sensation that provokes an urge to scratch. Many stimuli (notably histamine) are able to induce pruritus. The neural conduction of the itch sensation from the free unmyelinated nerve endings to the central nervous system mainly occurs on unmyelinated C fibres and the anterolateral spinothalam...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039020-00005

    authors: Lorette G,Vaillant L

    更新日期:1990-02-01 00:00:00

  • Activity of quinolones against mycobacteria.

    abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00004

    authors: Jacobs MR

    更新日期:1999-01-01 00:00:00

  • Current concepts in diabetic gastroparesis.

    abstract::Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363130-00002

    authors: Smith DS,Ferris CD

    更新日期:2003-01-01 00:00:00

  • Olaratumab: First Global Approval.

    abstract::Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0680-2

    authors: Shirley M

    更新日期:2017-01-01 00:00:00

  • Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

    abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549010-00008

    authors: Haria M,Bryson HM

    更新日期:1995-01-01 00:00:00

  • The role of proton pump inhibitors in gastro-oesophageal reflux disease.

    abstract::The proton pump inhibitors (PPIs) are the most successful class of drugs that have been introduced for the treatment of gastro-oesophageal reflux disease (GORD) because of their profound and consistent effect on gastric acid secretion. The PPIs have demonstrated an excellent adverse effect profile after approximately ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464030-00004

    authors: Dekel R,Morse C,Fass R

    更新日期:2004-01-01 00:00:00

  • Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

    abstract::The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447020-00003

    authors: Luqmani R,Gordon C,Bacon P

    更新日期:1994-02-01 00:00:00

  • Guidelines for general practitioners administering thrombolytics.

    abstract::Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550040-00004

    authors: Rawles J

    更新日期:1995-10-01 00:00:00

  • Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.

    abstract::Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01130-z

    authors: Schehlein EM,Robin AL

    更新日期:2019-07-01 00:00:00

  • Prospects for the development of new treatments with a rapid onset of action in affective disorders.

    abstract::Several compounds have been claimed to have a faster onset of antidepressant action. However, these trials suffered from lack of appropriate definitions and of standardised and comparable methodology, as far as measurement instruments, dosage strategies and statistical analyses were concerned. This article was underta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00001

    authors: Soares JC,Gershon S

    更新日期:1996-10-01 00:00:00

  • Use of oral rehydration therapy in acute watery diarrhoea. A practical guide.

    abstract::Various foods and fluids have been used in traditional treatments for diarrhoeal illnesses in infants and children for centuries. During the last 2 decades, however, with the advent of an improved scientific understanding of oral rehydration, effective treatment of dehydrating diarrhoea has been improved, expanded and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141040-00005

    authors: Sack DA

    更新日期:1991-04-01 00:00:00

  • Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.

    abstract::In type 1 and 2 diabetes mellitus patients, hyperglycaemia is independently related to the development of microvascular and macrovascular complications. Glycaemic targets and the benefits of intensive versus conventional glucose control are under debate. The purpose of this review is to provide an overview of the rand...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585220-000000000-00000

    authors: Mattila TK,de Boer A

    更新日期:2010-12-03 00:00:00

  • Drug-resistant tuberculosis: what are the treatment options?

    abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11585440-000000000-00000

    authors: Albanna AS,Menzies D

    更新日期:2011-05-07 00:00:00

  • Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

    abstract::Chenodeoxycholic acid (chenic acid; CDCA) is 1 of the 3 major biliary bile acids in man. When administered in pharmacological doses it causes a decrease in cholesterol saturation of bile, which in turn may lead to gradual dissolution of cholesterol gallstones. The stone dissolution rate during CDCA therapy has varied ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121020-00002

    authors: Iser JH,Sali A

    更新日期:1981-02-01 00:00:00

  • Platelets, thrombosis and drugs.

    abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197509010-00003

    authors: Mustard JF,Packham MA

    更新日期:1975-01-01 00:00:00

  • Drug-induced agranulocytosis.

    abstract::An unexpected precipitous fall in peripheral leucocyte count may occur during treatment of certain sensitised individuals with drugs usually well tolerated by most people. Three basic mechanisms for drug sensitivity have been found. One is characterised by sudden destruction of large numbers of leucocytes in periphera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197815020-00003

    authors: Pisciotta V

    更新日期:1978-02-01 00:00:00

  • Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

    abstract::When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059060-00004

    authors: Kaakkola S

    更新日期:2000-06-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • Prescribing oral contraceptives.

    abstract::The combined oral contraceptive pill is the most popular method of contraception worldwide, with modern low-dose formulations significantly improving tolerability. Breakthrough bleeding is the most significant adverse event associated with the low-dose combined oral contraceptives. Monophasic, biphasic, triphasic and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549020-00007

    authors: Weisberg E

    更新日期:1995-02-01 00:00:00

  • Albumin-bound Paclitaxel: in metastatic breast cancer.

    abstract::A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distributi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666070-00007

    authors: Robinson DM,Keating GM

    更新日期:2006-01-01 00:00:00

  • Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

    abstract::The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753040-00003

    authors: Jouzeau JY,Terlain B,Abid A,Nédélec E,Netter P

    更新日期:1997-04-01 00:00:00

  • Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

    abstract::Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855040-00002

    authors: Opal SM,Yu RL Jr

    更新日期:1998-04-01 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00